Aytu BioScience is a drug manufacturers-specialty & generic business based in the US. Aytu BioScience shares (AYTU) are listed on the NASDAQ and all prices are listed in US Dollars. Aytu BioScience employs 164 staff and has a trailing 12-month revenue of around $104.1 million.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $1.55 |
|---|---|
| 52-week range | $1.38 - $4.88 |
| 50-day moving average | $1.73 |
| 200-day moving average | $2.44 |
| Wall St. target price | $5.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-12.26 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.55 from 2023-09-22
| 1 week (2023-09-15) | -4.32% |
|---|---|
| 1 month (2023-08-24) | -11.43% |
| 3 months (2023-06-23) | -7.19% |
| 6 months (2023-03-24) | -28.90% |
| 1 year (2022-09-23) | 715.79% |
|---|---|
| 2 years (2021-09-24) | -47.81% |
| 3 years (2020-09-24) | 12 |
| 5 years (2018-09-24) | 26.1 |
| Revenue TTM | $104.1 million |
|---|---|
| Gross profit TTM | $52.3 million |
| Return on assets TTM | -8.8% |
| Return on equity TTM | -62.86% |
| Profit margin | -30.81% |
| Book value | $10.83 |
| Market Capitalization | $9.1 million |
TTM: trailing 12 months
We're not expecting Aytu BioScience to pay a dividend over the next 12 months.
Aytu BioScience's shares were split on a 1:20 basis on 5 January 2023. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aytu BioScience shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Aytu BioScience shares which in turn could have impacted Aytu BioScience's share price.
Over the last 12 months, Aytu BioScience's shares have ranged in value from as little as $1.38 up to $4.88. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aytu BioScience's is -0.3658. This would suggest that Aytu BioScience's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Aytu BioScience has bucked the trend.
Aytu Biopharma, Inc. , a commercial-stage pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates into two segments Rx segment and Consumer Health segment. The Rx segment consisting of prescription pharmaceutical products sold through third party wholesalers. The Consumer Health segment, which consists of various consumer health products sell directly to consumers. It also offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from six years and older; and Cotempla XR-ODT for the treatment of ADHD in patients from six to seventeen years old. In addition, the company provides Karbinal ER, for the treatment of seasonal and perennial allergies; and Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency.
Everything we know about the Discord IPO, plus information on how to buy in.
We’ve pulled a list together of the meme stocks being mentioned most on Reddit in the past 24 hours.
Steps to owning and managing TOTA, with 24-hour and historical pricing before you buy.
Steps to owning and managing TOT, with 24-hour and historical pricing before you buy.
Steps to owning and managing THBR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBE, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEF, with 24-hour and historical pricing before you buy.
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNK, with 24-hour and historical pricing before you buy.
Steps to owning and managing IPHA, with 24-hour and historical pricing before you buy.